Dalargin and electropuncture for acute hearing injury after mine blasts — RU2323019C1
Patent disclosure · 2008
- What the patent describes
- Patent report of 123 patients with blast-associated mixed hearing loss receiving Dalargin plus electropuncture; historical/prototype methods are compared.
- Reported evidence
- The patent describes 123 patients with blast-related mixed hearing injury. Its tables report complete restoration in 22.3%, improvement in 34.7% and no effect in 43% following combined treatment. Tinnitus improvement is also reported.
Reported patent results
Reported findings
Hearing improved in some patients, while 43% had no reported treatment effect.
Patent report of 123 patients with blast-associated mixed hearing loss receiving Dalargin plus electropuncture; historical/prototype methods are compared.
Population or model Patent report of 123 patients with blast-associated mixed hearing loss receiving Dalargin plus electropuncture; historical/prototype methods are compared.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Hearing outcome | 22.3% complete restoration, 34.7% improvement, 43% unchanged | Reported proportions; no modern randomized comparison established · After the treatment course |
| Hearing thresholds | Average reductions reported in the 15–30 dB range | Within-cohort change across speech/high frequencies · p<0.05 reported |
| Tinnitus | 49 patients reported complete disappearance; 9 less intensity; 5 unchanged | 63/123 had tinnitus initially; percentages in the source use the whole cohort denominator |
| Comparison with prior methods | Complete restoration 22.3% versus 7.3% and 9.8%; no effect 43% versus 67% and 64% | Comparator cohort sizes and concurrent comparability are not established |
Combined procedures, heterogeneous injuries, unclear comparator allocation and inconsistent percentage totals prevent a reliable Dalargin-alone effect estimate.
Source for these results ↗ · Reviewed 2026-11-06
Patent claims and provenance
Use. A Dalargin method relating to blast-associated hearing injury; disease-specific patent claims do not establish routine clinical benefit.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- RU2323019C1 ↗ · 2008-04-27
- Earliest priority / filing
- 2006-11-23 / 2006-11-23
- Original applicant / assignee
- Государственное образовательное учреждение высшего профессионального образования "Северо-Осетинская государственная медицинская академия" Федерального агентства по здравоохранению и социальному развитию
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 39453032 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Method for treating patients for posttraumatic sensorineural deafness in acute stage caused by mine explosion injury
Inventors: Эльвира Татаркановна Гаппоева (RU); Эльвира Татаркановна Гаппоева.
Study limitations and source details
Study limitations
- Patent case material does not establish randomized allocation, blinding or Dalargin monotherapy efficacy.
- One narrative passage reverses the restoration/improvement percentages; the summary follows the results tables.
- Mixed middle- and inner-ear injuries and associated procedures limit attribution.
Source details
Selected source text and metadata checked; full risk-of-bias review pending.
Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.
Sources checked
Citation
Author unconfirmed. Dalargin and electropuncture for acute hearing injury after mine blasts — RU2323019C1 Russian patent RU2323019C1